Posts by: Magdalena Kegel

Magdalena Kegel

Magdalena is a writer with a passion for bridging the gap between the people performing research, and those who want or need to understand it. She writes about medical science and drug discovery. She holds an MS in Pharmaceutical Bioscience and a PhD — spanning the fields of psychiatry, immunology, and neuropharmacology — from Karolinska Institutet in Sweden.

January 31, 2018January 31, 2018

Gentiopicroside Effectively Fights Lung Fibrosis, Chinese Mouse Study Finds

News

A natural compound called gentiopicroside effectively lowers inflammation and tissue scarring in a mouse model of pulmonary fibrosis (PF), say researchers at China’s Kunming Medical University. Since the plant-derived compound targets ... Read more

January 22, 2018January 22, 2018

PFF Survey Shows Few ILD Patients Get Correct Diagnosis First Time Around

News

Only a minority of patients with interstitial lung disease (ILD) swiftly receive a correct diagnosis, while more than half are misdiagnosed at least once, finds a Pulmonary Fibrosis Foundation (PFF) survey ... Read more

January 3, 2018January 3, 2018

Molecular Insights Pinpoint Cancer Therapy as Potential Lung Fibrosis Treatment

News

A cancer drug in clinical development might be used to treat pulmonary fibrosis (PF), or as a starting point to develop better antifibrotic treatments, German researchers suggest. Their study, “FoxO3 ... Read more

December 20, 2017December 20, 2017

Lung Cancer in IPF Patients Best Treated on ‘Do No Harm’ Basis, Commentary Argues

Esbriet, News

The management of patients with idiopathic pulmonary fibrosis (IPF) and lung cancer should follow the premise “first, do no harm,” researchers argue in the journal The Lancet Respiratory Medicine. Their ... Read more

December 13, 2017December 18, 2017

British Regulators Pave Way for Pulmonary Fibrosis Patients to Gain Early Access to Prometic Therapy

News

British regulators have paved the way for people with severe cases of pulmonary fibrosis to gain access to Prometic Life Sciences’ tissue-scarring therapy PBI-4050 before it is approved. The step the ... Read more

December 11, 2017December 11, 2017

Protein That Attracts Immune Cells to Lungs Contributes to Scarring, Study Reports

News

Researchers have found another piece in the molecular puzzle of changes leading to pulmonary fibrosis — a cell signaling factor. It offers scientists a new target for developing lung-scarring treatments. ... Read more

December 7, 2017December 7, 2017

Inhaled Thyroid Hormone May Work to Reverse Lung Fibrosis in IPF, Mouse Study Suggests

News

Thyroid hormone, delivered through aerosol inhalation, helped to resolve lung scarring in a mouse model of idiopathic pulmonary fibrosis (IPF), according to research published in the journal Nature Medicine. The ... Read more

October 19, 2017October 19, 2017

Breathlessness and Cough Signal Pulmonary Fibrosis Years Before Diagnosis, Study Reports

News

Patients with idiopathic pulmonary fibrosis (IPF) are likely to experience symptoms for years before their diagnosis, a British study reports. University of Nottingham researchers analyzed symptoms in the medical charts of ... Read more

October 5, 2017October 5, 2017

Autoimmune Processes May Drive IPF Progression, Vimentin Study Claims

News

Autoimmunity may drive idiopathic pulmonary fibrosis (IPF), according to a study that found a link between certain autoantibodies —those that target the body’s own cells and tissues — and disease ... Read more

September 28, 2017

Patara’s Trial Data Supports PA101 as Chronic Cough Treatment in IPF

News

Clinical trial results of Patara Pharma’s inhaled therapy candidate PA101 for chronic cough caused by idiopathic pulmonary fibrosis (IPF) indicate the medication reduces cough in a disease-specific manner. The findings, ... Read more